Truist Financial Cuts Biogen Stock Price Target

Analysts Downgrade Biotech Firm's Outlook Amid Uncertainty

Apr. 13, 2026 at 5:27pm

Got story updates? Submit your updates here. ›

An extreme close-up of a complex array of industrial machinery and equipment in muted metallic tones, conveying the intricate financial and institutional forces shaping the outlook for a major biotechnology company.Truist Financial's downgrade of Biogen's stock price target signals broader uncertainty around the biotech firm's prospects.San Diego Today

Truist Financial, a major financial services firm, has lowered its price target for Biogen (NASDAQ:BIIB) stock from $193 to $189 and maintained a 'hold' rating on the biotechnology company's shares. This comes as several other equity research analysts have also weighed in on Biogen's outlook, with a mix of price target adjustments and rating changes.

Why it matters

Biogen is a prominent biotech firm known for its multiple sclerosis treatments, and its stock performance is closely watched by investors. Truist's downgrade signals potential challenges ahead for the company, which could impact its market valuation and investor sentiment.

The details

In a research note issued on Monday, Truist Financial analysts cut their price target on Biogen from $193 to $189 while keeping a 'hold' rating on the stock. This follows a number of other analyst actions on Biogen in recent months, including Wolfe Research setting a $231 target and Tudor Pickering establishing a $201 price objective. Overall, the consensus rating on Biogen is 'Hold' based on data from MarketBeat, with an average price target of $206.81.

  • Truist Financial issued its updated research note on Biogen on Monday, April 13, 2026.

The players

Truist Financial

A major U.S. financial services firm that provides banking, insurance, and investment services.

Biogen

A leading biotechnology company focused on developing treatments for neurological and neurodegenerative diseases, including multiple sclerosis.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Biogen's future financial performance and any further updates from analysts on the company's outlook.

The takeaway

Truist Financial's downgrade of Biogen's stock price target reflects broader uncertainty around the biotech firm's prospects, underscoring the need for the company to deliver strong results to maintain investor confidence.